Our findings suggest that APP may therefore represent a new therapeutic target and/or biomarker for FXS and for other neurodevelopmental disorders and intellectual disabilities, such as ASD, that share with FXS the dysregulation of APP processing. The gene discussed is APP; the disease is fragile X syndrome.